TIDMAMS
RNS Number : 0969Z
Advanced Medical Solutions Grp PLC
16 September 2020
16 September 2020
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Interim Results for the six months ended 30 June 2020
Winsford, UK, 16 September 2020: Advanced Medical Solutions
Group plc (AIM: AMS), the surgical and advanced woundcare
specialist company, today announces its unaudited interim results
for the six months ended 30 June 2020.
Financial Highlights:
GBP million H1 2020 H1 2019 Reported
change
Group revenue 39.3 48.7 -19%
-------- -------- ---------
Operating margin (%) 11.3 23.4 -52%
-------- -------- ---------
Adjusted (1) operating margin
(%) 14.0 26.7 -47%
-------- -------- ---------
Profit before tax 4.3 11.2 -62%
-------- -------- ---------
Adjusted(1) profit before tax 5.3 12.8 -59%
-------- -------- ---------
Diluted earnings per share (p) 1.68 4.06 -59%
-------- -------- ---------
Adjusted(1) diluted earnings
per share (p) 2.16 4.80 -55%
-------- -------- ---------
Net operating cash flow 8.8 10.3 -14%
-------- -------- ---------
Net cash(2) 67.9 63.9 +6%
-------- -------- ---------
Interim dividend per share (p) 0.50 0.50 +0%
-------- -------- ---------
Business Highlights (including post period end):
Throughout this unprecedented period, AMS has retained its
employee base in safe conditions and maintained supply to hospitals
and other healthcare providers. The Group has remained profitable
and cash generative whilst continuing to invest in R&D and
maintaining its dividends. With COVID-19 impacts expected to reduce
in each subsequent quarter and balance sheet strength, the Group is
well positioned to return to strong growth as our underlying
markets continue to recover.
-- Trading was in line with our trading update of 9 July 2020,
with the majority of the business impacted by government-led
restrictions to control COVID-19 and a slowdown in demand across
all regions and product categories
-- All manufacturing sites have remained in operation throughout
the COVID-19 pandemic, servicing customers and order demand, and
having implemented strict controls to ensure employee safety at all
times
-- First half revenue was GBP39.3 million (2019 H1 GBP48.7
million) down by 19% on a reported and constant currency(3)
basis
-- Despite the significant challenges, the Group reported an
adjusted operating profit of GBP5.5 million (2019 H1: GBP13.0
million) and an increase in net cash to GBP67.9 million (2019 H1:
GBP63.9 million)
-- Investment in R&D increased to GBP3.8 million (2019 H1:
GBP2.9 million) as progress continued on all core projects across
the Group
-- US LiquiBand(R) recovery plan remains on track with sales
initiatives recovering 2% share of end market volumes. LiquiBand(R)
Rapid launched with a key partner as planned and regained product
listings on the two previously lost Group Purchasing Organisation
(GPO) contracts
-- Product approvals for new geographies have continued with our
first approvals in India for both LiquiBand(R) and
LiquiBandFix8(R)
-- Patents granted for LiquiBand(R) Exceed in the UK and US,
providing protection and tax benefits until 2034
-- Interim dividend maintained at 0.50p per share (2019 H1:
0.50p) payable on 23 October 2020 to shareholders on the register
at the close of business on 25 September 2020. The Board expects to
return to dividend growth in the near future, as business returns
to normal.
Commenting on the interim results, Chris Meredith, Chief
Executive Officer of AMS, said: "The Group has faced an
unprecedented first half of the year as a result of the severe
impact on our core markets arising from the COVID-19 pandemic. As a
business, we have responded well to the challenge, prioritising our
employees' safety and continuing critical supply to customers.
Whilst the short-term impact has been stark, we are proud that the
Group remains profitable and cash generative during this time
whilst maintaining a robust balance sheet.
T he Group has maintained investment in R&D to progress its
key projects and is well positioned for growth as our markets
continue to recover. Whilst we expect COVID-19 to continue to
impact sales and profitability in the short term, the Board remains
positive about our medium to long-term prospects."
- End -
Notes
1 Adjusted profit before tax is shown before exceptional items
which, in 2020 H1 were GBPnil (2019 H1: GBP0.9 million), before
amortisation of acquired intangible assets which, in 2020 H1, were
GBP1.1 million (2019 H1: GBP0.7 million) and a credit of GBP0.03
million (2019 H1: GBPnil) due to a change in the fair value of
long-term liability as defined in the financial review. Adjusted
operating margin is shown before exceptional items and amortisation
of acquired intangible assets.
2 Net cash in 2020 H1 was GBP67.9 million (2019 H1: GBP63.9
million) defined as cash and cash equivalents of GBP68.4 million
(2019 H1: GBP63.9 million) plus short-term investments less
financial liabilities and bank loans in 2020 H1 of GBP0.5 million
(2019 H1: GBPnil)
3 Constant currency adjusts for the effect of currency movements
by re-translating the current period's performance at the previous
period's exchange rates
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Olivia
Manser
Investec Bank plc (NOMAD) & Broker Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence / Patrick
Robb
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, and
internal fixation devices, which it markets under its brands
LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also
supplies wound care dressings such as silver alginates, alginates
and foams through its ActivHeal(R) brand as well as under white
label. In 2019, the Group made two acquisitions: Sealantis, an
Israeli medical device company with a patent-protected sealant
technology platform; and Biomatlante, an established developer and
manufacturer of innovative surgical biomaterial technologies based
in France.
AMS's products, manufactured in the UK, the Netherlands,
Germany, France, the Czech Republic and Israel, are sold globally
via a network of multinational or regional partners and
distributors, as well as via AMS's own direct sales forces in the
UK, Germany, France, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK and Germany, Israel and France.
Established in 1991, the Group has approximately 700 employees. For
more information, please see www.admedsol.com.
Chief Executive's Review
Group performance
This has been an unprecedented period for the Group and, as
previously announced, the COVID-19 pandemic has had a significant
impact on trading within both divisions, primarily due to the
consequential reduction in elective surgery volumes. Despite the
challenges, we have continued to invest in R&D and progressed
our key projects, ensuring we are well placed to exploit future
growth opportunities across the Group as conditions normalise.
Business Unit performance
Surgical Business Unit
The Surgical Business Unit includes tissue adhesives, sutures,
biosurgical devices and internal fixation devices marketed under
the AMS brands LiquiBand(R) , RESORBA(R) and LiquiBandFix8(R) . In
the first half of 2020, Surgical revenues decreased by 19% to
GBP21.4 million (2019 H1: GBP26.5 million).
Surgical Business 2020 2019 Reported Growth
Unit H1 GBP'000 H1 GBP'000 Growth at constant
currency
Advanced Closure 8,875 13,605 (35%) (35%)
------------ ------------ --------- -------------
Internal Fixation
and Sealants 967 1,179 (18%) (18%)
------------ ------------ --------- -------------
Traditional Closure 6,188 7,189 (14%) (13%)
------------ ------------ --------- -------------
Biosurgical Devices 5,398 4,518 19% 21%
------------ ------------ --------- -------------
TOTAL 21,428 26,491 (19%) (19%)
------------ ------------ --------- -------------
Advanced Closure
Advanced Closure comprises predominantly the LiquiBand(R)
topical skin adhesive range of products, incorporating medical
cyanoacrylate adhesives in combination with purpose-built
applicators. These products are used to close and protect a broad
variety of surgical and traumatic wounds.
Advanced Closure 2020 2019 Reported Growth
H1 GBP'000 H1 GBP'000 Growth at constant
currency
Americas 5,094 7,927 (36%) (37%)
------------ ------------ --------- -------------
UK/Germany 1,956 3,353 (42%) (41%)
------------ ------------ --------- -------------
Rest of World 1,825 2,325 (22%) (22%)
------------ ------------ --------- -------------
TOTAL 8,875 13,605 (35%) (35%)
------------ ------------ --------- -------------
Revenues decreased by 35% to GBP8.9 million (2019 H1: GBP13.6
million) as demand fell in all territories due to lockdown measures
that resulted in much lower volumes for all categories of surgical
procedure. The US and UK markets were most heavily impacted as
these were the hardest hit by the pandemic, resulting in lockdowns
that were longer and more widespread.
Sales initiatives focused on US LiquiBand(R) started to recover
some momentum resulting in strong end sales volumes in Q1 2020 and
a 2% market share gain in the period. Q2 2020 volumes were much
reduced, as anticipated, due to the various restrictions in place
but we are pleased to have retained our increased market share
position for the full H1.
The LiquiBand (R) Rapid(TM) launch went ahead with one of the
Group's main US partners as planned and LiquiBand (R) is now
already l isted on both of the major US GPO contracts that were
lost in 2019.
Development on our lead LiquiBand(R) XL formulation continues to
progress well, and we expect to rerun the clinical study in Q3 2020
- keeping us on track to file for 510K in Q1 2021. In the run up to
this, we have implemented some short-term commercial agreements
with US hospitals to encourage additional LiquiBand(R) adoption,
which have contributed to the recent market share improvement. Once
approved, LiquiBand(R) XL is expected to unlock further growth
potential in the LiquiBand(R) business with all partners.
We continue to obtain approvals for LiquiBand(R) in new
geographies and notably obtained approval for LiquiBand(R) in India
in the first half of the year. We are in the process of selecting
our best route-to-market partner for this market and anticipate
launch in 2021.
While there is continued uncertainty and varying state-by-state
impacts of COVID-19, it has been encouraging to see that, by
August, end market sales volumes for medical adhesives in the US
had already recovered to more than 80% of its historical
(pre-COVID-19) usage rate.
Internal Fixation and Sealants
This category comprises our LiquiBandFix8(R) devices, indicated
for the internal fixation of hernia meshes using our LiquiBand (R)
technology. LiquiBandFix8(R) is used to fix the hernia meshes in
place inside the body with accurately delivered individual drops of
cyanoacrylate adhesive, instead of traditional tacks and staples.
Global hernia surgery volumes are especially impacted by the
COVID-19 pandemic as the vast majority are considered non-essential
elective surgery resulting in revenue decreasing by 18% to GBP1.0
million (2019 H1: GBP1.2 million).
Despite the restrictions and reduced surgical procedures, we are
pleased to have made significant progress in both product training
and product approvals. We have delivered virtual symposia in
association with prominent hernia societies attended by more than
8,000 surgeons from around the world to increase awareness of the
reduced post-operative clinical complications when using
LiquiBandFix8(R) instead of staples or tacks. We also obtained H1
approvals for LiquiBandFix8(R) in other geographies, notably in
India and Brazil, with distributor selection and launch planning
now in process. Entry into the US market for Fix8(R) requires a
Pre-Market Approval process and successful completion of our
clinical trial that commenced in August 2019. Although all clinical
activity was suspended for approximately six months, we are pleased
to report that all five sites are now enrolling patients again and
one third of procedural volumes have been completed. We expect to
file for FDA approval in 2022 and continue to be excited about the
long-term prospects for the LiquiBandFix8(R) portfolio with entry
into the US being a significant milestone for the Group.
Following the acquisition of Sealantis in 2019, we have used the
Medical Device Directive (MDD) extension period to work with our
Notified Body in making progress towards gaining our first CE
approval for the Seal G laparoscopic device. We have also expanded
the existing CE approval for the open device to include a blue
visual indicator that significantly aids visibility for the surgeon
during product usage. These approvals are both expected before the
end of 2020 along with the start of the first clinical trial,
delayed due to the postponement of all patient recruitment since
March 2020. In October, we also expect to complete our commercial
soft launch research activity with 30 European Key Opinion Leaders
ahead of full European commercial launch which is on track for H1
2021.
Traditional Closure
The Traditional Closure category includes our RESORBA(R) branded
Absorbable and Non-absorbable Suture ranges which include certain
surgical specialties (such as dental and ophthalmic) and are sold
in Germany and numerous other territories. Due to the COVID-19
pandemic, revenue decreased by 14% to GBP6.2 million or 13% at
constant currency (2019 H1: GBP7.2 million).
The Group continues to assess further opportunities to expand
its suture offering.
Biosurgical Devices
The Biosurgical Devices category principally comprises
RESORBA(R) antibiotic loaded collagen sponges, collagen membranes
and cones and oxidised cellulose. Following the Biomatlante
acquisition, synthetic bone substitutes and bio-absorbable screws
have been added to this category. Despite the impacts of the
COVID-19 pandemic, Biosurgical revenue increased by 19% to GBP5.4
million (2019 H1: GBP4.5 million) and by 21% at constant currency,
reflecting the inclusion of Biomatlante sales following its
acquisition by the Group in November 2019. We expect to make
significant progress selling Biomatlante products under the RESORBA
(R) brand through our existing sales infrastructure and we made
some initial sales into Germany in the first half of the year.
Collagen loaded with Vancomycin has been sold in Germany for
several years on a named patient prescription only basis and we
continue to progress a full CE mark to allow broader promotion and
sales. We are currently progressing with an MDD application but
will move to proceed under Medical Device Regulation (MDR) if
necessary. We also continue to work with both EU and US regulators
on wider market approvals for our antibiotic loaded collagen
pacemaker pouch, also currently sold via prescription in Germany .
FDA guidance has indicated the need for further clinical work which
we intend to start in Europe in 2021.
Our innovative MBCP(R) synthetic bone substitutes are approved
for use in Europe and the US and represent most of our current
Biomatlante sales. To access another significant part of the
market, we have developed a freeze dried bone substitute (FDBS),
which has strong cohesive properties when mixed with fluids and can
be easily moulded for optimal placement in orthopaedic and spine
surgery. The US approval process is progressing well and we expect
to file for 510K before the end of 2020. European approval under
MDR is expected to follow in the next few years. The FDBS platform
will also open up opportunities for the addition of active
ingredients such as platelets, stem cells or synthetic
peptides.
Woundcare Business Unit
The Woundcare Business Unit is comprised of our multi-product
portfolio of advanced woundcare dressings and bulk materials, sold
under partner brands, plus the AMS branded ActivHeal(R) range, sold
predominantly to the NHS.
In the first half of 2020, revenue decreased by 20% to GBP17.9
million (2019 H1: GBP22.2 million) driven by factors associated
with the COVID-19 pandemic such as lower wound treatment volumes
globally, deferral of elective surgery, the temporary closure of
wound clinics and lack of community and long-term care services. In
addition, the year-on-year comparator was affected by some
customers' Brexit preparations in 2019.
Woundcare Business 2020 2019 Reported Growth
Unit H1 GBP'000 H1 GBP'000 Growth at constant
currency
Infection Management 7,281 9,407 (23%) (23%)
------------ ------------ --------- -------------
Exudate Management 7,205 10,082 (29%) (29%)
------------ ------------ --------- -------------
Other Woundcare 3,368 2,734 23% 22%
------------ ------------ --------- -------------
TOTAL 17,854 22,223 (20%) (20%)
------------ ------------ --------- -------------
The Business Unit has continued its regulatory activity during
the first half of the year and has successfully obtained MDD
extensions until 2024 for all the remaining products in its
woundcare range. Consequently, the Group has secured the maximum
time possible to complete compliance with the new MDR certification
requirements.
Even as volumes trend back towards pre-COVID-19 levels, we
remain cautious about our advanced wound care prospects, given the
previous year's low market growth rates and some of the ongoing
consolidation activity. We do however remain confident that MDR
transitions will provide opportunities for us along with optimism
around our new product pipeline.
Infection Management
The infection management category comprises advanced woundcare
dressings that incorporate antimicrobials such as Silver and
Polyhexamethylene Biguanide (PHMB). Revenue decreased by 23% to
GBP7.3 million (2019 H1: GBP9.4 million).
During the first half of the year, we launched our Silver
Moisture Wicking Fabric product with one partner in the US and
signed a distribution agreement with a second partner who has
placed launch orders for the second half of the year. Silver
high-performance dressings also launched with a second US partner
in the first half of the year but hampered by the inability to meet
customers and promote products.
Our PHMB foam range provides access to the large, growing
antimicrobial foam market and demonstrates enhanced product
performance in terms of rapid microbial activity and eradication of
pathogens. The new Silicone version that provides gentle but secure
adhesion obtained US approval in 2019 and we are filing for EU
approval in 2020 in advance of the extended MDD deadline.
The R&D pipeline also includes a device for the debridement
of wounds which we expect to launch into the US in 2021 whilst also
exploring options for European approval.
Looking ahead, the Group continues to work on developing next
generation high-gelling products with differentiated antibiofilm
claims and an application of our tissue scaffold in a woundcare
environment.
Exudate Management
Exudate management comprises advanced woundcare dressings and
gels which do not incorporate any antimicrobial elements. Revenue
decreased by 29% to GBP7.2 million (2019 H1: GBP10.1 million)
predominantly due to the COVID-19 impact on woundcare activity in
general.
We have continued with our initiative to find and appoint new
distribution partners in markets where our key partners have no or
low presence but the demand for a high quality, cost effective
wound care dressing range still exists. A few new contracts have
been signed in the first half of the year, contributing more than
GBP1 million of additional sales over the next five years.
Registrations are also being pursued in additional territories with
a view to further exploiting this growth opportunity.
With the heightened attention on the prevention of pressure
ulcers in all major markets, we were pleased to successfully add a
pressure ulcer prevention indication to our US silicone foam
range.
Other Woundcare
Other Woundcare comprises royalties, fees and woundcare
sealants. Revenue increased by 23% at reported currency and by 22%
at constant currency to GBP3.4 million (2019 H1: GBP2.7 million)
mainly due to higher royalty income from the Group's licensing
arrangement with Organogenesis.
COVID-19
The Group's priority continues to be the safety, health and
well-being of its employees and their families. Having taken
appropriate steps, all AMS sites have remained in operation
throughout the pandemic meaning it has been able to maintain the
supply of its vital medical devices to healthcare partners and
customers worldwide whilst complying with government measures on
social distancing. As part of this, AMS has:
-- Enabled working from home arrangements for all roles that can do so;
-- Utilised Government job retention schemes where employees
were unable to carry out their role;
-- Set up a designated team to closely monitor and risk assess
the impact of COVID-19 on our operations and taken steps to
establish safe working practices in all AMS sites;
-- Undertaken a full evaluation of our supply chain to ensure
any risks are identified and mitigated;
-- Adjusted working patterns and put in place controls to
minimise interactions and ensure social distancing; and
-- Maintained our payment terms to support all of the Group's suppliers.
The Group confirms it is in robust financial condition to
weather the continued global disruption and retains a strong net
cash position of GBP67.9 million and an undrawn unsecured GBP80
million credit facility, which is committed until December
2023.
Regulatory
As a result of the COVID-19 pandemic, the deadline for Notified
Bodies to review Medical Device Directive (MDD) certificates was
extended by one year to May 2021, allowing AMS and other suppliers
additional time to get new products approved or existing products
reapproved under MDD. The end date, when all MDD certificates
become invalid, remains as 26 May 2024.
As mentioned above, AMS is utilising the MDD extension to file
for new product approvals in 2020 including Sealantis enhancements
and Silicone PHMB dressings.
In the first half of 2020, AMS successfully completed its final
MDD recertifications so that all products now have extended MDD
certificates allowing ample time for compliance with the new
European Medical Devices Regulation (MDR) by 2024. AMS is well
prepared for the stricter requirements on product safety and
performance, clinical evaluation and post-market clinical evidence
stipulated by MDR and in the first half of the year submitted its
first three MDR files for Notified Body review.
Our extensive preparations leave us well placed to exploit
opportunities that will undoubtedly arise in the next few years
during the implementation of MDR.
Brexit
Having completed a comprehensive review of Brexit related risks,
we continue to prepare for the possibility of a 'No Deal' Brexit.
We have reassigned our UK product certificates to BSI Netherlands
and appointed Advanced Medical Solutions BV as EU Authorised
Representative for our UK manufactured products. We are maintaining
increased stock holdings on all sites and continue to have
extensive planning conversations with our customers.
Summary and outlook
The Group expects the sales impact of COVID-19 to gradually
reduce in the second half of 2020 and as we move into 2021, as
global lockdowns are eased and a version of normality returns. We
are seeing significant variability in the pace of recovery for
different geographies and different types of surgical procedures,
and with the potential for second waves of COVID-19 infection, it
remains difficult to accurately predict the full year financial
impact on the Group. We are pleased, however, that we continue to
make good progress on key R&D initiatives, and with our US
LiquiBand (R) recovery plan and robust financial position, we
anticipate a strong recovery once conditions normalise.
We are encouraged by the improved trading since Q2 and the Group
is starting to see signs of recovery in most markets. Second half
trading to date in 2020 is in line with Board expectations that
were communicated in July 2020.
Financial Review
IFRS reporting
To provide the clearest possible insight into our performance,
the Group uses alternative performance measures. These measures are
not defined in International Financial Reporting Standards (IFRS)
and, therefore, are considered to be non-GAAP (Generally Accepted
Accounting Principles) measures. Accordingly, the relevant IFRS
measures are also presented where appropriate. We use such measures
consistently at the half year and full year and reconcile them as
appropriate. The measures used in this statement include constant
currency revenue growth, adjusted operating margin, adjusted profit
before tax, adjusted earnings per share and adjusted net cash
inflow from operating activities, allowing the impacts of exchange
rate volatility, exceptional items, amortisation and the change in
fair value of long-term liability to be separately identified. Net
cash is an additional non-GAAP measure used.
Overview
Revenue decreased by 19% at reported and constant currency to
GBP39.3 million (2019 H1: GBP48.7 million).
Excluding exceptional items, administration expenses increased
marginally to GBP16.9 million (2019: GBP16.6 million) inclusive of
losses arising from foreign exchange movements as effective cost
management and the utilisation of Government job retention schemes
were offset by higher amortisation of intangibles. The Group
operated its factories at much lower volumes, resulting in
under-absorption of its fixed costs and, to reflect the need for
operational staff to continue attending our sites during the
lockdown period, additional one-off payments were made to these
employees totalling GBP0.3 million. The Group incurred GBP3.8
million of gross R&D spend in the period (2019 H1: GBP2.9
million), representing 9.6% of sales (2019 H1: 5.9%) which, whilst
impacted by a decrease in sales, also reflects an ongoing
investment in innovation and in accommodating the heightened
regulatory environment.
No exceptional costs have been incurred in the six-month period
(2019 H1: GBP0.9 million).
Amortisation of acquired intangible assets was GBP1.1 million in
the six-month period (2019 H1: GBP0.7 million) due to the full
period effect of the acquisition of Sealantis in January 2019 and
Biomatlante in November 2019.
Adjusted operating profit which excludes amortisation of
acquired intangibles and exceptional costs, decreased by 57.7% to
GBP5.5 million (2019 H1: GBP13.0 million) whilst the adjusted
operating margin decreased by 1,270 bps to 14.0% (2019 H1: 26.7%)
due to the negative impact of the COVID-19 pandemic on the Group's
revenues.
The Group generated adjusted profit before tax of GBP5.3 million
(2019 H1: GBP12.8 million) and profit before tax of GBP4.3 million
(2019 H1: GBP11.2 million).
Reconciliation of profit before tax to adjusted profit before
tax
-------------------------------------------------------------------
Unaudited Unaudited
Six months Six months
ended ended
30 June 20 30 June 19
GBP'000 GBP'000
---------------------------------------- ------------ -----------
Profit before tax 4,260 11,219
Amortisation of acquired intangibles 1,074 682
Exceptional items - 920
Change in FV of long-term liability (29) -
---------------------------------------- ------------ -----------
Adjusted profit before tax 5,305 12,821
---------------------------------------- ------------ -----------
The Group's effective tax rate, reflecting the blended tax rates
in the countries where we operate and including UK patent box
relief, decreased to 14.4% (2019 H1: 21.8%). The decrease was due
to patent box claims relating to the newly granted LiquiBand (R)
Exceed patents which can be retrospectively claimed.
Adjusted diluted earnings per share decreased by 55% to 2.16p
(2019 H1: 4.80p) and diluted earnings per share decreased by 59% to
1.68p (2019 H1: 4.06p).
The Board intends to pay an interim dividend of 0.50p per share
on 23 October 2020 to shareholders on the register at the close of
business on 25 September 2020. This is in line with the interim
dividend paid in the first half of 2019. The Board expects to
return to dividend growth in the near future, as business returns
to normal.
Operating result by business segment
Six months ended 30 June Surgical Woundcare
2020
GBP'000 GBP'000
--------------------------------- --------- ----------
Revenue 21,428 17,854
Profit from operations 1,951 2,779
Amortisation of acquired
intangibles 1,069 5
Adjusted profit from operations
(4) 3,020 2,784
Adjusted operating margin
(4) 14.1% 15.6%
--------------------------------- --------- ----------
Six months ended 30 June
2019
Revenue 26,491 22,223
Profit from operations 8,251 4,309
Amortisation of acquired
intangibles 678 4
Adjusted profit from operations
(4) 8,929 4,313
Adjusted operating margin
(4) 33.7% 19.4%
--------------------------------- --------- ----------
(4) Adjusted for exceptional items and for amortisation of
acquired intangible assets
Table is reconciled to statutory information in note 5 of the
financial information.
Surgical
Surgical revenues decreased by 19% to GBP21.4 million (2019 H1:
GBP26.5 million) at both reported currency and at constant
currency. Adjusted operating margin decreased 1,960 bps to 14.1%
(2019 H1: 33.7%) as the Group was unable to offset costs in the
same proportion to the decrease in revenue and as a result of
increased investment in R&D, clinical and regulatory
affairs.
Woundcare
Woundcare revenues decreased by 20% to GBP17.9 million (2019 H1:
GBP22.2 million) at reported currency and by 20% at constant
currency. Adjusted operating margin decreased by 380 bps to 15.6%
(2019 H1: 19.4%).
Currency
The Group hedges significant currency transaction exposure by
using forward contracts, and aims to hedge approximately 80% of its
estimated transactional exposure for the next 12 to 18 months. In
the first half of the year, approximately one third of sales were
invoiced in Euros and approximately one quarter were invoiced in US
Dollars. The Group estimates that a 10% movement in the GBP:US$ or
GBP:EUR exchange rate will impact Sterling revenues by
approximately 2.4% and 3.5% respectively and in the absence of any
hedging this would have an impact on profit of 1.8% and 0.6%.
Cash Flow
Net cash inflow from operating activities reduced by 14% to
GBP8.8 million (2019 H1: GBP10.3 million) predominantly due to a
reduction in operating profit, partially offset by positive working
capital movements.
Reconciliation of Net cash inflow from operating activities
to Adjusted net cash inflow from operating activities
--------------------------------------------------------------------
Unaudited Unaudited
Six months Six months
ended ended Change
30 June 30 June
20 19
GBP'000 GBP'000
-------------------------------- ----------- ----------- --------
Net cash inflow from operating
activities 8,817 10,261 -14.1%
Exceptional items - 920 -100.0%
-------------------------------- ----------- ----------- --------
Adjusted net cash inflow from
operating activities 8,817 11,181 -21.1%
-------------------------------- ----------- ----------- --------
At the end of the period, the Group had net cash of GBP67.9
million (31 December 2019: GBP64.1 million).
In the first half of 2020, receivables reduced by GBP11.9
million due to lower sales (2019 H1: GBP2.2 million) with debtor
days at 43 (2019 H1: 41 days) and payables reduced by GBP1.1
million (2019 H1: GBP2.8 million) with creditor days at 30 (2019
H1: 26 days). Inventory increased to 7.8 months of supply in the
period (2019 H1: 5.0 months of supply) as sales shortfalls in the
year have led to increased inventory holdings. Whilst we intend to
continue to hold higher than usual stocks to mitigate possible
Brexit and COVID-19 supply risks, a reduction in Inventory levels
is planned for the second half of the year.
In the period, we invested GBP2.4 million in capital equipment,
R&D and regulatory costs including investment in converting and
packaging machines (2019 H1: GBP2.6 million).
Tax payments increased to GBP3.3 million (2019 H1: GBP2.9
million) which is GBP2.7 million higher than tax in the income
statement due to a one-off change in timing of payments on account
in the UK. A back-dated claim for UK patent box relief will be made
in respect of the LiquiBand (R) Exceed patent and the Group
therefore expect tax payments to be significantly lower in the
second half of the year.
In June 2020, the Group paid its final dividend for the year
ended 31 December 2019 of GBP2.3 million (2019 H1: GBP1.9
million).
The Group has an unsecured, undrawn GBP80 million,
multi-currency credit facility provided jointly by HSBC and
NatWest, which is in place until December 2023. This facility
carries an annual interest rate of LIBOR or EURIBOR plus a margin
that varies between 0.60% and 1.70% depending on the Group's net
debt to EBITDA ratio.
CONDENSED CONSOLIDATED INCOME STATEMENT
(Unaudited) (Unaudited) (Audited)
Six months ended Six months ended Year ended 31 December
30 June 2020 30 June 2019 2019
Before Exceptional Before Exceptional Before Exceptional
Exceptional Items Exceptional Items Exceptional Items
Note Note Note
Items 7 Total Items 7 Total Items 7 Total
Note GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
---------------- ----- ------------ ------------ --------- ------------ ------------ --------- ------------ ------------ ---------
Revenue from
continuing
operations 5 39,282 - 39,282 48,714 - 48,714 102,368 - 102,368
Cost of sales (17,540) - (17,540) (19,500) - (19,500) (41,885) - (41,885)
---------------- ----- ------------ ------------ --------- ------------ ------------ --------- ------------ ------------ ---------
Gross profit 21,742 - 21,742 29,214 - 29,214 60,483 - 60,483
Distribution
costs (483) - (483) (459) - (459) (997) - (997)
Administration
costs (16,949) - (16,949) (16,607) (920) (17,527) (34,566) (1,053) (35,619)
Other income 115 - 115 157 - 157 376 - 376
Profit from
operations 4,425 - 4,425 12,305 (920) 11,385 25,296 (1,053) 24,243
Finance income 166 - 166 200 - 200 406 - 406
Finance costs (331) - (331) (366) - (366) (392) - (392)
Profit before
taxation 4,260 - 4,260 12,139 (920) 11,219 25,310 (1,053) 24,257
Income tax 8 (614) - (614) (2,446) - (2,446) (5,338) - (5,338)
---------------- ----- ------------ ------------ --------- ------------ ------------ --------- ------------ ------------ ---------
Profit for
the period
attributable
to equity
holders
of the parent 3,646 - 3,646 9,693 (920) 8,773 19,972 (1,053) 18,919
---------------- ----- ------------ ------------ --------- ------------ ------------ --------- ------------ ------------ ---------
Earnings per
share
Basic 4 1.70p - 1.70p 4.53p (0.43p) 4.10p 9.30p (0.49p) 8.81p
Diluted 4 1.68p - 1.68p 4.48p (0.43p) 4.06p 9.21p (0.49p) 8.72p
Adjusted
diluted
(5) 4 2.16p - 2.16p 4.80p (0.43p) 4.37p 9.83p (0.49p) 9.34p
---------------- ----- ------------ ------------ --------- ------------ ------------ --------- ------------ ------------ ---------
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE
INCOME
(Unaudited) (Unaudited) (Audited)
Six months ended Six months ended Year ended
30 June 2020 30 June 2019 31 December 2019
GBP'000 GBP'000 GBP'000
---------------- ----- ------------ ------------ --------- ------------ ------------ --------- ------------ ------------ ---------
Profit for
the year 3,646 8,773 18,919
---------------- ----- ------------ ------------ --------- ------------ ------------ --------- ------------ ------------ ---------
Exchange differences on translation
of foreign operations 6,733 930 (3,538)
(Loss)/gain arising on cash
flow hedges (1,759) 284 3,091
Deferred tax charge arising
on cash flow hedges 130 - (130)
--------------------------------------------------- --------- ------------ ------------ --------- ------------ ------------ ---------
Other comprehensive credit/(charge)
for the period 5,104 1,214 (577)
--------------------------------------------------- --------- ------------ ------------ --------- ------------ ------------ ---------
Total comprehensive income for
the period attributable to equity
holders of the parent 8,750 9,987 18,342
--------------------------------------------------- --------- ------------ ------------ --------- ------------ ------------ ---------
(5) Adjusted for exceptional items, amortisation of acquired
intangible assets and for change in the fair value of long-term
liability
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(Unaudited) (Unaudited) (Audited)
30 June 30 June 31 December
20 19 19
Note GBP'000 GBP'000 GBP'000
Assets
Non-current assets
Acquired intellectual property
rights 10,095 9,654 9,478
Intangible assets 16,134 14,875 15,985
Software intangibles 2,665 2,983 2,832
Development costs 6,103 3,696 5,039
Goodwill 57,470 52,333 53,558
Property, plant and equipment 27,629 27,563 27,707
Loans and other financial assets - 30 -
Deferred tax assets - 179 96
Trade and other receivables 223 321 531
--------------------------------------- ----- ------------ ------------ ------------
120,319 111,634 115,226
Current assets
Inventories 23,653 16,298 17,655
Trade and other receivables 17,603 23,288 29,221
Current tax assets 1,001 22 129
Cash and cash equivalents 68,355 63,888 64,751
--------------------------------------- ----- ------------ ------------ ------------
110,612 103,496 111,756
--------------------------------------- ----- ------------ ------------ ------------
Total assets 230,931 215,130 226,982
--------------------------------------- ----- ------------ ------------ ------------
Liabilities
Current liabilities
Trade and other payables 12,577 11,086 14,043
Current tax liabilities - 2,267 1,781
Lease liabilities 1,140 983 1,353
13,717 14,336 17,177
Non-current liabilities
Trade and other payables 3,470 3,540 3,150
Other loans 498 - 664
Deferred tax liabilities 6,863 5,934 6,409
Lease liabilities 8,070 8,567 8,347
18,901 18,041 18,570
--------------------------------------- ----- ------------ ------------ ------------
Total liabilities 32,618 32,377 35,747
--------------------------------------- ----- ------------ ------------ ------------
Net assets 198,313 182,753 191,235
--------------------------------------- ----- ------------ ------------ ------------
Equity
Share capital 11 10,764 10,738 10,745
Share premium 36,284 36,072 36,226
Share-based payments reserve 10,211 8,343 9,466
Investment in own shares (161) (159) (159)
Share-based payments deferred tax
reserve 417 729 649
Other reserve 1,531 1,531 1,531
Hedging reserve (1,074) (2,122) 555
Translation reserve 6,484 4,219 (249)
Retained earnings 133,857 123,402 132,471
--------------------------------------- ----- ------------ ------------ ------------
Equity attributable to equity holders
of the parent 198,313 182,753 191,235
--------------------------------------- ----- ------------ ------------ ------------
CONDENSED CONSOLIDATED Statement of Changes in Equity
Attributable to equity holders of the Group
Share- Investment Share-based
Share Share based in own payments Other Hedging Translation Retained
deferred
capital premium payments shares tax reserve reserve reserve earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 1 January
2020
(audited) 10,745 36,226 9,466 (159) 649 1,531 555 (249) 132,471 191,235
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Consolidated
profit for
the period
to 30 June
2020 - - - - - - - - 3,646 3,646
Other
comprehensive
income - - - - - - (1,629) 6,733 - 5,104
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Total
comprehensive
income - - - - - - (1,629) 6,733 3,646 8,750
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share-based
payments - - 795 - - - - - - 795
Share options
exercised 19 58 (50) - (232) - - - - (205)
Shares
purchased by
EBT - - - (375) - - - - - (375)
Shares sold by
EBT - - - 373 - - - - - 373
Dividends paid - - - - - - - - (2,260) (2,260)
----------- ------------ -------- -------- ------------
At 30 June
2020
(unaudited) 10,764 36,284 10,211 (161) 417 1,531 (1,074) 6,484 133,857 198,313
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share- Investment Share-based
Share Share based in own payments Other Hedging Translation Retained
deferred
capital premium payments shares tax reserve reserve reserve earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 1 January
2019
(audited) 10,674 35,192 7,333 (156) 708 1,531 (2,406) 3,289 116,560 172,725
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Consolidated
profit for
the period
to 30 June
2019 - - - - - - - - 8,773 8,773
Other
comprehensive
income - - - - - - 284 930 - 1,214
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Total
comprehensive
income - - - - - - 284 930 8,773 9,987
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share-based
payments - - 1,065 - - - - - - 1,065
Share options
exercised 64 880 (55) - 21 - - - - 910
Shares
purchased by
EBT - - - (603) - - - - - (603)
Shares sold by
EBT - - - 600 - - - - - 600
Dividends paid - - - - - - - - (1,931) (1,931)
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 30 June
2019
(unaudited) 10,738 36,072 8,343 (159) 729 1,531 (2,122) 4,219 123,402 182,753
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share- Investment Share-based
Share Share based in own payments Other Hedging Translation Retained
deferred
capital premium payments shares tax reserve reserve reserve earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 1 January
2019
(audited) 10,674 35,192 7,333 (156) 708 1,531 (2,406) 3,289 116,560 172,725
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Consolidated
profit for
the year
to 31
December 2019 - - - - - - - - 18,919 18,919
Other
comprehensive
income - - - - - - 2,961 (3,538) - (577)
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Total
comprehensive
income - - - - - - 2,961 (3,538) 18,919 18,342
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
Share-based
payments - - 1,856 - (59) - - - - 1,797
Share options
exercised 71 1,034 277 - - - - - - 1,382
Shares
purchased by
EBT - - - (603) - - - - - (603)
Shares sold by
EBT - - - 600 - - - - - 600
Dividends paid - - - - - - - - (3,008) (3,008)
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
At 31 December
2019
(audited) 10,745 36,226 9,466 (159) 649 1,531 555 (249) 132,471 191,235
--------------- -------- -------- --------- ----------- ------------ -------- -------- ------------ --------- --------
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited) (Unaudited) (Audited)
Six months Six months
ended ended Year ended
30 June 30 June 31 December
20 19 19
GBP'000 GBP'000 GBP'000
-------------------------------------------- ------------ ------------ ------------
Cash flows from operating activities
Profit from operations 4,425 11,385 24,243
Adjustments for:
Depreciation 1,700 1,603 3,154
Amortisation - intellectual property
rights 1,074 682 1,683
- development costs 251 244 492
- software intangibles 256 218 519
Increase in inventories (5,357) (1,361) (2,454)
Decrease/(increase) in trade and other
receivables 11,260 2,162 (574)
Decrease in trade and other payables (2,269) (2,798) (1,275)
Share-based payments expense 795 1,065 1,856
Taxation (3,318) (2,939) (5,945)
Net cash inflow from operating activities 8,817 10,261 21,699
-------------------------------------------- ------------ ------------ ------------
Cash flows from investing activities
Purchase of software (52) (662) (826)
Capitalised research and development (1,217) (730) (2,355)
Purchases of property, plant and equipment (1,141) (1,231) (2,673)
Disposal of property, plant and equipment 120 - 4
Interest received 166 199 422
Acquisition of subsidiary (39) (18,408) (24,145)
Net cash used in investing activities (2,163) (20,832) (29,573)
-------------------------------------------- ------------ ------------ ------------
Cash flows from financing activities
Dividends paid (2,260) (1,931) (3,008)
Repayment of principal under lease
liabilities (493) (486) (925)
Issue of equity shares 60 907 1,066
Shares purchased by EBT (375) (603) (603)
Shares sold by EBT 373 600 600
Interest paid (347) (366) (709)
Repayment of secured loan (176) - -
Net cash used in financing activities (3,218) (1,879) (3,579)
-------------------------------------------- ------------ ------------ ------------
Net increase/(decrease) in cash and
cash equivalents 3,436 (12,450) (11,453)
Cash and cash equivalents at the beginning
of the period 64,751 76,391 76,391
Effect of foreign exchange rate changes 168 (53) (187)
Cash and cash equivalents at the end
of the period 68,355 63,888 64,751
-------------------------------------------- ------------ ------------ ------------
Notes Forming Part of the Consolidated Financial Statements
1. Reporting entity
Advanced Medical Solutions Group plc ("the Company") is a public
limited company incorporated and domiciled in England and Wales
(registration number 2867684). The Company's registered address is
Premier Park, 33 Road One, Winsford Industrial Estate, Cheshire,
CW7 3RT.
The Company's ordinary shares are traded on the AIM market of
the London Stock Exchange plc. The consolidated financial
statements of the Company for the six months ended 30 June 2020
comprise the Company and its subsidiaries (together referred to as
the "Group").
The Group is primarily involved in the design, development and
manufacture of surgical and advanced woundcare products for sale
into the global medical device market.
2. Basis of preparation
The information for the period ended 30 June 2020 does not
constitute statutory accounts as defined in section 434 of the
Companies Act 2006. A copy of the statutory accounts for the year
ended 31 December 2019 has been delivered to the Registrar of
Companies. The auditor reported on those accounts; their report was
unqualified, did not draw attention to any matters of emphasis
without qualifying the report and did not contain a statement under
section 498 (2) or (3) of the Companies Act 2006.
The individual financial statements for each Group company are
presented in the currency of the primary economic environment in
which it operates (its functional currency). For the purpose of the
consolidated financial statements, the results and financial
position of each Group company are expressed in pounds sterling,
which is the functional currency of the Company and the
presentation currency for the consolidated financial
statements.
3. Accounting policies
The same accounting policies, presentations and methods of
computation are followed in the condensed set of financial
statements as applied in the Group's latest annual audited
financial apart from the adoption of the following new or amended
IFRS and Interpretations issued by the International Accounting
Standards Board (IASB):
- Amendments to References to the Conceptual Framework in IFRS Standards
- Definition of a Business (Amendments to IFRS 3)
- Definition of Material (amendments to IAS 1 and IAS 8)
- Interest Rate Benchmark Reform (Amendments to IFRS 9, IAS 39 and IFRS7)
No revised standards adopted in the current period have had a
material impact on the Group's financial statements.
The unaudited condensed set of financial statements included in
this half-yearly financial report have been prepared in accordance
with International Accounting Standard 34 'Interim Financial
Reporting', as adopted by the European Union. These condensed
interim accounts should be read in conjunction with the annual
accounts of the Group for the year ended 31 December 2019. The
annual financial statements of Advanced Medical Solutions Group plc
are prepared in accordance with International Financial Reporting
Standards as adopted by the European Union.
4. Earnings per share
(Unaudited) (Unaudited)
Six months Six months (Audited)
ended ended Year ended
30 June 30 June 31 December
2020 2019 2019
Number of shares '000 '000 ' 000
------------------------------------- ------------ ------------ ------------
Weighted average number of ordinary
shares for the purposes of basic
earnings per share 214,985 213,876 214,730
------------------------------------- ------------ ------------ ------------
Effect of dilutive potential
ordinary shares: share options,
deferred share bonus, LTIPs 2,585 2,452 2,107
------------------------------------- ------------ ------------ ------------
Weighted average number of ordinary
shares for the purposes of diluted
earnings per share 217,570 216,328 216,837
------------------------------------- ------------ ------------ ------------
Basic EPS is calculated by dividing the earnings attributable to
ordinary shareholders by the weighted average number of shares
outstanding during the period.
Diluted EPS is calculated on the same basis as basic EPS but
with the further adjustment to the weighted average shares in issue
to reflect the effect of all potentially dilutive share options.
The number of potentially dilutive share options is derived from
the number of share options and awards granted to employees where
the exercise price is less than the average market price of the
Company's ordinary shares during the period.
Adjusted earnings per share
Adjusted EPS is calculated after adding back exceptional items,
amortisation of acquired intangible assets and change in the fair
value of long-term liability and is based on earnings of:
(Unaudited) (Unaudited)
Six months Six months (Audited)
ended ended Year ended
30 June 30 June 31 December
2020 2019 2019
GBP'000 GBP'000 GBP'000
---------------------------------------- ------------ ------------ ------------
Earnings
Profit for the year being attributable
to equity holders of the parent 3,646 8,773 18,919
Exceptional items - 920 1,053
Amortisation of acquired intangible
assets 1,074 682 1,683
Change in the fair value of long-term
liability (29) - (345)
Adjusted profit for the year being
attributable to equity holders of the
parent 4,691 10,375 21,310
---------------------------------------- ------------ ------------ ------------
pence pence Pence
---------------------------------------- ------------ ------------ ------------
Adjusted basic EPS 2.18p 4.85p 9.92p
Adjusted diluted EPS 2.16p 4.80p 9.83p
---------------------------------------- ------------ ------------ ------------
The denominators used are the same as those detailed above for
both basic and diluted earnings per share.
The adjusted diluted EPS information is considered to provide a
fairer representation of the Group's trading performance.
5. Segment information
Segment results, assets and liabilities include items directly
attributable to a segment as well as those that can be allocated on
a reasonable basis. Unallocated items comprise mainly investments
and related revenue, corporate assets, head office expenses,
exceptional items, income tax assets and the Group's external
borrowings. These are the measures reported to the Group's Chief
Executive for the purposes of resource allocation and assessment of
segment performance.
Business segments
The principal activities of the business units are as
follows:
Surgical
Selling, marketing and innovation of the Group's surgical
products either sold directly by our sales teams or by
distributors.
Woundcare
Selling, marketing and innovation of the Group's advanced
woundcare products supplied under partner brands, bulk materials
and the ActivHeal brand predominantly to the UK NHS.
Segment information about these Business Units is presented
below:
Six months ended
30 June 2020 Surgical Woundcare Consolidated
(Unaudited) GBP'000 GBP'000 GBP'000
-------------------------------------- --------- ---------- -------------
Revenue 21,428 17,854 39,282
-------------------------------------- --------- ---------- -------------
Result
-------------------------------------- --------- ---------- -------------
Adjusted segment operating profit 3,020 2,784 5,804
Amortisation of acquired intangibles (1,069) (5) (1,074)
Segment operating profit 1,951 2,779 4,730
Unallocated expenses (305)
Exceptional items -
-------------
Profit from operations 4,425
Finance income 166
Finance costs (331)
-------------------------------------- --------- ---------- -------------
Profit before tax 4,260
Tax (614)
-------------------------------------- --------- ---------- -------------
Profit for the period 3,646
-------------------------------------- --------- ---------- -------------
At 30 June 2020
(Unaudited) Surgical Woundcare Consolidated
Other information GBP'000 GBP'000 GBP'000
-------------------------------- --------- ---------- -------------
Capital additions:
Software intangibles 25 27 52
Development 647 570 1,217
Property, plant and equipment 663 478 1,141
Depreciation and amortisation (2,261) (1,020) (3,281)
-------------------------------- --------- ---------- -------------
Balance sheet
Assets
Segment assets 163,143 67,467 230,610
Unallocated assets 321
-------------------------------- --------- ----------
Consolidated total assets 230,931
-------------------------------- --------- ---------- -------------
Liabilities
Segment liabilities 18,160 14,458 32,618
-------------------------------- --------- ---------- -------------
Consolidated total liabilities 32,618
-------------------------------- --------- ---------- -------------
Six months ended
30 June 2019 Surgical Woundcare Consolidated
(Unaudited) GBP'000 GBP'000 GBP'000
-------------------------------------- --------- ---------- -------------
Revenue 26,491 22,223 48,714
-------------------------------------- --------- ---------- -------------
Result
-------------------------------------- --------- ---------- -------------
Adjusted segment operating profit 8,929 4,313 13,242
Amortisation of acquired intangibles (678) (4) (682)
Segment operating profit 8,251 4,309 12,560
Unallocated expenses (255)
Exceptional items (920)
-------------
Profit from operations 11,385
Finance income 200
Finance costs (366)
-------------------------------------- --------- ---------- -------------
Profit before tax 11,219
Tax (2,446)
-------------------------------------- --------- ---------- -------------
Profit for the period 8,773
-------------------------------------- --------- ---------- -------------
At 30 June 2019
(Unaudited) Surgical Woundcare Consolidated
Other information GBP'000 GBP'000 GBP'000
-------------------------------- --------- ---------- -------------
Capital additions:
Software intangibles 293 369 662
Development 455 275 730
Property, plant and equipment 734 497 1,231
Depreciation and amortisation (1,817) (930) (2,747)
-------------------------------- --------- ---------- -------------
Balance sheet
Assets
Segment assets 151,021 63,656 214,677
Unallocated assets 453
-------------------------------- --------- ----------
Consolidated total assets 215,130
-------------------------------- --------- ---------- -------------
Liabilities
Segment liabilities 19,267 13,110 32,377
-------------------------------- --------- ---------- -------------
Consolidated total liabilities 32,377
-------------------------------- --------- ---------- -------------
Year ended
31 December 2019 Surgical Woundcare Consolidated
(Audited) GBP'000 GBP'000 GBP'000
-------------------------------------- --------- ---------- -------------
Revenue 56,544 45,824 102,368
-------------------------------------- --------- ---------- -------------
Result
-------------------------------------- --------- ---------- -------------
Adjusted segment operating profit 16,086 11,378 27,464
Amortisation of acquired intangibles (1,675) (8) (1,683)
Segment operating profit 14,411 11,370 25,781
Unallocated expenses (485)
Exceptional items (1,053)
-------------
Profit from operations 24,243
Finance income 406
Finance costs (392)
-------------------------------------- --------- ---------- -------------
Profit before tax 24,257
Tax (5,338)
-------------------------------------- --------- ---------- -------------
Profit for the year 18,919
-------------------------------------- --------- ---------- -------------
Year ended
31 December
(Audited) Surgical Woundcare Consolidated
Other information GBP'000 GBP'000 GBP'000
-------------------------------- --------- ---------- -------------
Capital additions:
Software intangibles 364 462 826
Development 1,346 1,009 2,355
Property, plant and equipment 1,393 1,280 2,673
Depreciation and amortisation (3,985) (1,863) (5,848)
-------------------------------- --------- ---------- -------------
Balance sheet
Assets
Segment assets 160,241 66,354 226,595
Unallocated assets 387
-------------------------------- --------- ----------
Consolidated total assets 226,982
-------------------------------- --------- ---------- -------------
Liabilities
Segment liabilities 21,647 14,100 35,747
-------------------------------- --------- ---------- -------------
Consolidated total liabilities 35,747
-------------------------------- --------- ---------- -------------
Geographical segments
The Group operates in the UK, Germany, the Netherlands, France,
the Czech Republic, Israel, with a sales office located in Russia
and a sales presence in the USA. In presenting information on the
basis of geographical segments, segment revenue is based on the
geographical location of customers. Segment assets are based on the
geographical location of the assets.
The following table provides an analysis of the Group's sales by
geographical market, irrespective of the origin of the goods or
services, based upon location of the Group's customers:
(Unaudited) (Unaudited) (Audited)
Six months ended Six months ended Year ended
30 June 2020 30 June 2019 31 December 2019
GBP'000 GBP'000 GBP'000
--------------------------------------------- ----------------- ----------------- -----------------
United Kingdom 7,349 8,971 20,151
Germany 9,234 10,437 20,018
Europe excluding United Kingdom and Germany 12,032 12,826 23,476
United States of America 8,922 14,473 34,879
Rest of World 1,745 2,007 3,844
--------------------------------------------- ----------------- ----------------- -----------------
39,282 48,714 102,368
--------------------------------------------- ----------------- ----------------- -----------------
The following table provides an analysis of the Group's total
assets by geographical location.
(Unaudited) (Unaudited) (Audited)
Six months ended Six months ended Year ended
30 June 2020 30 June 2019 31 December 2019
GBP'000 GBP'000 GBP'000
----------------------------------------------------- ----------------- ----------------- -----------------
United Kingdom 114,466 112,794 117,055
Germany 73,163 69,024 69,502
Israel 24,478 25,961 23,175
France 10,291 - 9,612
Europe excluding United Kingdom, Germany and France 4,924 4,912 5,106
United States of America 3,609 2,439 2,532
230,931 215,130 226,982
----------------------------------------------------- ----------------- ----------------- -----------------
6. Financial Instruments' fair value disclosures
It is the policy of the Group to enter into forward foreign
exchange contracts to cover specific foreign currency payments and
receipts.
The Group held the following financial instruments at fair value
at 30 June 2020. The Group has no financial instruments with fair
values that are determined by reference to significant unobservable
inputs i.e. those that would be classified as level 3 in the fair
value hierarchy, nor have there been any transfers of assets or
liabilities between levels of the fair value hierarchy. There are
no non-recurring fair value measurements.
The following table details the forward foreign currency
contracts outstanding as at the period end:
Ave. exchange rate Foreign currency Fair value
30 June 30 June 31 Dec 30 June 30 June 31 Dec 30 June 30 June 31 Dec
20 19 19 20 19 19 20 19 19
USD:GBP1 USD:GBP1 USD:GBP1 USD'000 USD'000 USD'000 GBP'000 GBP'000 GBP'000
Cash flow
hedges
Sell US
dollars
Less than
3 months 1.300 1.406 1.386 9,000 9,500 9,000 (363) (690) (307)
3 to 6
months 1.241 1.444 1.328 8,500 7,500 8,000 (17) (665) (5)
7 to 12
months 1.299 1.363 1.271 14,000 16,000 17,500 (526) (705) 615
Over 12
months 1.253 1.338 1.301 10,000 5,000 12,500 (87) (140) 262
----------- --------- --------- --------- -------- -------- -------- -------- -------- --------
41,500 38,000 47,000 (993) (2,200) 56
----------- --------- --------- --------- -------- -------- -------- -------- -------- --------
Ave. exchange rate Foreign currency Fair value
30 June 30 June 31 Dec 30 June 30 June 31 Dec 30 June 30 June 31 Dec
20 19 19 20 19 19 20 19 19
EUR:GBP1 EUR:GBP1 EUR:GBP1 EUR'000 EUR'000 EUR'000 GBP'000 GBP'000 GBP'000
Cash flow
hedges
Sell Euros
Less than
3 months 1.138 1.112 1.125 900 960 620 (28) 2 23
3 to 6
months 1.074 1.108 1.143 600 960 1,200 12 2 25
7 to 12
months 1.144 1.137 1.112 1,200 1,820 1,500 (47) 46 61
Over 12
months 1.112 1.139 1.144 1,000 900 1,200 (18) 28 12
------------ --------- --------- --------- -------- -------- -------- -------- -------- --------
3,700 4,640 4,520 (81) 78 121
------------ --------- --------- --------- -------- -------- -------- -------- -------- --------
7. Exceptional items
During the six months ended 30 June 2020, the Group incurred
exceptional items of GBPnil (2019 H1: GBP0.9 million in relation to
the acquisition and integration of Sealantis as well as the
transaction costs to participate in another potential process which
was ultimately unsuccessful , year ended 31 December 2019: GBP1.1
million in relation to the acquisition and integration of Sealantis
and Biomatlante as well as the transaction costs to participate in
another potential process which was ultimately unsuccessful ).
8. Taxation
The weighted average tax rate for the Group for the six month
period ended 30 June 2020 was 14.4% (first half of 2019: 21.8%,
year ended 31 December 2019: 22.0%). The Group's effective tax rate
for the full year is expected to be 14.4%, which has been applied
to the six months ended 30 June 2020 (first half of 2019: 21.8%,
year ended 31 December 2019: 22.0%). This represents a significant
decrease on previous periods as the Group is able to
retrospectively claim for patent box relief as a result of the
granting of patents on LiquiBand(R) Exceed in the first half of
2020.
9. Dividends
(Unaudited) (Unaudited) (Audited)
Six months Six months
ended ended Year ended
30 June 30 June 31 December
2020 2019 2019
Amounts recognised as distributions
to equity holders in the period: GBP'000 GBP'000 GBP'000
------------------------------------- ------------ ------------ ------------
Final dividend for the year ended
31 December 2018 of 0.90p per
ordinary share - 1,931 1,931
Interim dividend for the year
ended 31 December 2019 of 0.50p
per ordinary share - - 1,077
Final dividend for the year ended
31 December 2019 of 1.05p per
ordinary share 2,260 - -
-------------------------------------
2,260 1,931 3,008
------------------------------------- ------------ ------------ ------------
10. Contingent liabilities
The Directors are not aware of any contingent liabilities faced
by the Group as at 30 June 2020 (30 June 2019: GBPnil, 31 December
2019: GBPnil).
11. Share capital
Share capital as at 30 June 2020 amounted to GBP10,764,000 (30
June 2019: GBP10,738,000, 31 December 2019: GBP10,745,000). During
the period the Group issued 371,467 shares in respect of exercised
share options, LTIPS, Deferred Annual Bonus Scheme and the Deferred
Share Bonus Scheme.
12. Going concern
In carrying out their duties in respect of going concern, the
Directors have carried out a review of the Group's financial
position and cash flow forecasts for the next 12 months. These have
been based on a comprehensive review of revenue, expenditure and
cash flows, taking into account specific business risks and the
current economic environment.
Due to the impact that COVID-19 has had on the global economy,
the Group has deemed it appropriate to use sensitivity analysis on
the Group's forecasted performance, using a mid-case scenario, a
10% sales reduction, and a worst-case scenario, a 25% sales
reduction. The results show that in both scenarios AMS is able to
continue its operations for a period of at least 12 months, and
importantly there remains significant margin between our covenants
in place.
With regards to the Group's financial position, it had cash and
cash equivalents at 30 June 2020 of GBP68.4 million and a
five-year, GBP80 million, multi-currency, revolving credit
facility, obtained in December 2018, with an accordion option under
which AMS can request up to an additional GBP20 million on the same
terms. The credit facility is provided jointly by HSBC and NatWest,
is subject to leverage and interest cover covenants, is unsecured
on the assets of the Group and is currently undrawn.
While the current economic environment is uncertain, AMS
operates in markets whose demographics are favourable, underpinned
by an increasing need for products to treat chronic and acute
wounds. Consequently, long-term market growth is expected. The
Group has a number of long-term contracts with customers across
different geographic regions and also with substantial financial
resources, ranging from government agencies through to global
healthcare companies.
After taking the above into consideration, the Directors have
reached the conclusion that the Group is well placed to manage its
business risks in the current economic environment. Accordingly,
they continue to adopt the going concern basis in preparing the
condensed consolidated financial statements.
13. Principal risks and uncertainties
Further detail concerning the principal risks affecting the
business activities of the Group is detailed on pages 46 and 47 of
the Annual Report and Accounts for the year ended 31 December 2019.
There have been no significant changes since the last annual
report, other than the uncertainty surrounding the COVID-19
pandemic, for which, an update has been provided in market
announcements and within these Interim Statements.
14. Seasonality of sales
There are no significant factors affecting the seasonality of
sales between the first and second half of the year.
15. Events after the balance sheet date
There have been no material events subsequent to the end of the
interim reporting period ended 30 June 2020.
16. Copies of the interim results
Copies of the interim results can be obtained from the Group's
registered office at Premier Park, 33 Road One, Winsford Industrial
Estate, Winsford, Cheshire, CW7 3RT and are available on our
website "www.admedsol.com".
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IR BCGDCRDBDGGU
(END) Dow Jones Newswires
September 16, 2020 02:00 ET (06:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From May 2023 to May 2024